Navigating ARTG Inclusion: Building a Smarter Regulatory Strategy for Australia

Freyr supports pharmaceutical companies in navigating Australia’s highly regulated and commercially significant healthcare market. As regulatory expectations continue to evolve, gaining inclusion in the Australian Register of Therapeutic Goods (ARTG) has become more than a procedural requirement—it is now a strategic business priority.

Australia’s Evolving Regulatory Landscape

Australia remains an attractive market for global pharmaceutical manufacturers. However, increasing scrutiny from the Therapeutic Goods Administration (TGA) has resulted in longer review timelines and more detailed evaluations of submissions.

To successfully supply therapeutic products in Australia, sponsors must obtain ARTG inclusion, which requires:

• CTD/eCTD-compliant dossiers
• Australia-specific Module 1 documentation
• GMP clearance for manufacturing facilities
• Robust quality, safety, and efficacy data

Even globally approved dossiers often require significant localization to align with Australian regulatory expectations.

Common Challenges Sponsors Face

Many organizations encounter avoidable delays and compliance issues during the submission process due to:

• Incomplete or inaccurate Module 1 localization
• GMP clearance delays for overseas manufacturing sites
• Multiple rounds of TGA queries
• Misalignment between global and local regulatory strategies
• Lack of structured post-approval lifecycle management

These challenges can extend approval timelines, increase operational costs, and create ongoing compliance risks.

How Freyr Supports ARTG Submission Success

Freyr delivers a precision-driven regulatory approach designed to help sponsors achieve efficient approvals and long-term compliance in Australia.

Regulatory Gap Assessment & Readiness Planning

We assess submission readiness early and identify regulatory gaps before filing.

TGA-Compliant Module 1 Preparation

Our experts develop and localize Module 1 documentation aligned with current TGA expectations.

End-to-End CTD/eCTD Publishing

Freyr provides comprehensive dossier compilation, formatting, validation, and publishing support.

GMP Clearance Coordination

We support GMP clearance activities through proactive authority coordination and regulatory liaison services.

Structured Query Management

Our teams help manage and respond to TGA queries efficiently, minimizing review cycles and approval delays.

Lifecycle Management Support

Freyr also supports post-approval compliance through structured lifecycle management and regulatory maintenance services.

Balancing Global Consistency with Local Compliance

For global pharmaceutical manufacturers, one of the biggest challenges is maintaining alignment between worldwide regulatory strategies and country-specific requirements.

Freyr bridges this gap by combining:

• Global regulatory expertise
• Deep local TGA knowledge
• Streamlined documentation and compliance processes

This integrated approach helps organizations reduce duplication, improve operational efficiency, and maintain consistency across multiple markets.

Regulatory Success Requires Long-Term Planning

In Australia, regulatory success is not just about achieving ARTG inclusion—it is about maintaining compliance throughout the product lifecycle.

Organizations that invest in submission readiness, localized regulatory planning, and proactive compliance management are better positioned for sustainable market success.